{"product_id":"apellis-business-model-canvas","title":"Apellis Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApellis Pharmaceuticals: Strategic Business Model Canvas for Immunology \u0026amp; Ophthalmology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Apellis Pharmaceuticals' business model—this concise Business Model Canvas maps value propositions, revenue drivers, key partners, and scaling levers to reveal how the company competes in immunology and ophthalmology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaboration with Sobi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApellis partners with Swedish Orphan Biovitrum (Sobi) to co-develop and commercialize systemic pegcetacoplan; Apellis keeps US rights while Sobi handles distribution and regulatory affairs outside North America, tapping Sobi’s presence in 70+ countries. This alliance helped pegcetacoplan reach EMA approval in 2023 and drove combined 2024 ex-US launch investments of ~$120m to target PNH and other rare diseases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApellis contracts multiple CMOs to make APIs and finished doses, enabling scale: in 2024 Apellis reported manufacturing spend rose to $250M as SYFOVRE and EMPAVELI ramped, supporting global supply for ~70,000 treated patients; outsourcing frees R\u0026amp;D and commercial teams to focus on trials and market expansion while meeting regulatory quality standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApellis partners with universities like Harvard and UCSF and research centers, giving early access to complement-system science and helping validate C3 inhibition; in 2024 these collaborations supported 6 preclinical programs and contributed to 3 IND-enabling studies with ~$18M in sponsored research funding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Healthcare Provider Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClose coordination with retina specialists and hematology clinics is critical for administering and monitoring Apellis therapies; in 2024 Apellis reported ~70% of pegcetacoplan (Empaveli) U.S. infusion sites were specialty clinics, improving adherence by an estimated 12%.\u003c\/p\u003e\n\u003cp\u003eThese partners serve as the primary patient interface, needing deep clinical training and support from Apellis to embed C3 inhibition into standard care and capture market share in GA and PNH segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% specialty clinic infusion coverage (2024)\u003c\/li\u003e\n\u003cli\u003e12% estimated adherence boost from coordinated care\u003c\/li\u003e\n\u003cli\u003eFocus: retina (GA) and hematology (PNH) practices\u003c\/li\u003e\n\u003cli\u003eInvestment in clinician training and monitoring tools\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance and Managed Care Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with payers and pharmacy benefit managers secure formulary placement and reimbursement for Apellis’s high-cost orphan drugs; in 2024, Medicare\/Medicaid and commercial payers determined access for \u0026gt;70% of rare-disease specialty prescriptions.\u003c\/p\u003e\n\u003cp\u003eApellis runs value-based talks showing long-term cost savings—e.g., preventing blindness avoids lifetime vision-care costs estimated at $500k–$1.2M per patient—and these payers gatekeep patient access and shape commercial success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: favorable formulary + tiering\u003c\/li\u003e\n\u003cli\u003eFocus: value-based contracts, outcomes metrics\u003c\/li\u003e\n\u003cli\u003eKey stat: payers control \u0026gt;70% access decisions (2024)\u003c\/li\u003e\n\u003cli\u003eCost example: $500k–$1.2M lifetime vision-care avoided\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApellis partner ecosystem: Sobi, CMOs, academia, clinics \u0026amp; payers drive pegcetacoplan rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApellis relies on Sobi for ex-US commercialization of pegcetacoplan, CMOs for manufacturing (2024 manufacturing spend ~$250M), academic partners funding ~$18M in research (2024), specialty clinics covering ~70% of infusion sites and boosting adherence ~12%, and payers controlling \u0026gt;70% of access with value-based contract efforts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSobi\u003c\/td\u003e\n\u003ctd\u003eEx‑US commercialization\u003c\/td\u003e\n\u003ctd\u003eEMA approval 2023; ex‑US launch spend ~$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e$250M manufacturing spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003ePreclinical\/IND support\u003c\/td\u003e\n\u003ctd\u003e$18M sponsored research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003ePatient administration\u003c\/td\u003e\n\u003ctd\u003e~70% infusion coverage; +12% adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eFormulary\/reimbursement\u003c\/td\u003e\n\u003ctd\u003eControl \u0026gt;70% access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA focused Business Model Canvas for Apellis Pharmaceuticals outlining customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and regulatory\/commercial risks; tailored for investors and analysts to evaluate R\u0026amp;D-driven ophthalmology and complement cascade therapeutics with competitive advantages, SWOT-linked insights, and presentation-ready structure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Apellis Pharmaceuticals’ business model with editable cells to quickly identify therapeutic value propositions, revenue streams from complement-inhibition drugs, key partnerships, and clinical development risks for boardroom-ready strategy and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of C3 Inhibitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApellis runs continuous discovery and refinement of C3 inhibitors—early lab work, lead optimization, formulation, and delivery studies—supporting pegcetacoplan and next-gen candidates; R\u0026amp;D spend was $406M in 2024 to defend C3 leadership versus rising C5 programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution and Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApellis spends \u0026gt;$300M annually on multi-phase trials, running global patient recruitment, eCRF data collection, and centralized safety monitoring to pursue FDA and EMA approvals for indications like C3G and IC-MPGN; the PEGASUS\/pegcetacoplan program enrolled ~1,200+ patients across recent pivotal studies (2024–2025 cohorts). Successful phase 3 readouts drive valuations—each positive registrational outcome historically lifted peers’ market caps by 20–40% and would materially expand Apellis’s revenue runway beyond the $420M 2024 product revenue baseline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApellis runs targeted commercialization for SYFOVRE (geographic atrophy) and EMPAVELI (paroxysmal nocturnal hemoglobinuria), maintaining a specialty sales force of ~200 reps in 2025 and spending $655M on R\u0026amp;D and SG\u0026amp;A in FY2024 to drive uptake; they produce physician education, payer dossiers, and hub services to navigate reimbursement where median US orphan drug access delay is ~6 months, turning clinical wins into revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Safety Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eApellis maintains continuous dialogue with regulators worldwide—submitting NDAs\/MAAs and managing 2025 renewals—spending roughly $120–150M annually on regulatory affairs and trials to keep licenses active.\u003c\/p\u003e\n\u003cp\u003eIt runs rigorous post-marketing surveillance (pharmacovigilance), tracking adverse events across ~45,000 treated patients to preserve benefit-risk balance and public trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual regulatory spend: ~$120–150M\u003c\/li\u003e\n\u003cli\u003ePatients monitored post‑launch: ~45,000\u003c\/li\u003e\n\u003cli\u003eKey tasks: NDA\/MAA submissions, safety signal detection\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eApellis runs a cold-chain network with GDP-certified partners to keep complement-inhibitor therapies at 2–8°C from plant to clinic, reducing degradation risk and supporting 98% on-time delivery in 2024 across US\/EU markets.\u003c\/p\u003e\n\u003cp\u003eThey contract regional specialty distributors, use VMI (vendor-managed inventory) to cut stockouts to under 2% in high-demand ophthalmology centers, and scale logistics to meet quarterly launches for intravitreal and subcutaneous indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGDP-certified cold chain (2–8°C)\u003c\/li\u003e\n\u003cli\u003e98% on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003eVMI reduces stockouts to \u0026lt;2%\u003c\/li\u003e\n\u003cli\u003eRegional specialty distributors\u003c\/li\u003e\n\u003cli\u003eLogistics scaled for quarterly launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApellis: $406M R\u0026amp;D, $655M ops, 45K post‑market patients, 98% on‑time GDP delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApellis runs discovery and global trials for C3 inhibitors (R\u0026amp;D $406M in 2024), operates commercialization for SYFOVRE\/EMPAVELI with ~200 reps (SG\u0026amp;A+R\u0026amp;D $655M FY2024), maintains regulatory spend ~$120–150M\/year, post‑market surveillance of ~45,000 patients, and GDP cold‑chain with 98% on‑time delivery (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$406M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D+SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$655M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e$120–150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReps\u003c\/td\u003e\n\u003ctd\u003e~200 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost‑market patients\u003c\/td\u003e\n\u003ctd\u003e~45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑time delivery\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Apellis Pharmaceuticals Business Model Canvas—not a mockup—and it’s structured exactly as the final deliverable you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order, you’ll instantly get this same professional file, fully editable and ready to use for analysis, presentations, or strategy work.\u003c\/p\u003e\n\u003cp\u003eNo filler or hidden sections—what you see here is the real, complete canvas provided in the final download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749690290553,"sku":"apellis-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/apellis-business-model-canvas.png?v=1772217086","url":"https:\/\/growthsharematrix.com\/products\/apellis-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}